The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Calabrese, J. R.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Calabrese, J. R.
Related Collections
* Bipolar Disorder
* Depression
* Atypical Neuroleptics
Am J Psychiatry 162:1351-1360, July 2005
© 2005 American Psychiatric Association

A Randomized, Double-Blind, Placebo-Controlled Trial of Quetiapine in the Treatment of Bipolar I or II Depression

Joseph R. Calabrese, M.D., Paul E. Keck Jr., M.D., Wayne Macfadden, M.D., Margaret Minkwitz, Ph.D., Terence A. Ketter, M.D., Richard H. Weisler, M.D., Andrew J. Cutler, M.D., Robin McCoy, R.N., Ellis Wilson, M.S., and Jamie Mullen, M.D.

The BOLDER Study Group

OBJECTIVE: There is a major unmet need for effective options in the treatment of bipolar depression. METHOD: Five hundred forty-two outpatients with bipolar I (N=360) or II (N=182) disorder experiencing a major depressive episode (DSM-IV) were randomly assigned to 8 weeks of quetiapine (600 or 300 mg/day) or placebo. The primary efficacy measure was mean change from baseline to week 8 in the Montgomery-Åsberg Depression Rating Scale total score. Additional efficacy assessments included the Hamilton Depression Rating Scale, Clinical Global Impression of severity and improvement, Hamilton Anxiety Rating Scale, Pittsburgh Sleep Quality Index, and Quality of Life Enjoyment and Satisfaction Questionnaire. RESULTS: Quetiapine at either dose demonstrated statistically significant improvement in Montgomery-Åsberg Depression Rating Scale total scores compared with placebo from week 1 onward. The proportions of patients meeting response criteria (≥50% Montgomery-Åsberg Depression Rating Scale score improvement) at the final assessment in the groups taking 600 and 300 mg/day of quetiapine were 58.2% and 57.6%, respectively, versus 36.1% for placebo. The proportions of patients meeting remission criteria (Montgomery-Åsberg Depression Rating Scale ≤12) were 52.9% in the groups taking 600 and 300 mg/day of quetiapine versus 28.4% for placebo. Quetiapine at 600 and 300 mg/day significantly improved 9 of 10 and 8 of 10 Montgomery-Åsberg Depression Rating Scale items, respectively, compared to placebo, including the core symptoms of depression. Treatment-emergent mania rates were low and similar for the quetiapine and placebo groups (3.2% and 3.9%, respectively). CONCLUSIONS: Quetiapine monotherapy is efficacious and well tolerated for the treatment of bipolar depression.




This article has been cited by other articles:


Home page
 Br. J. PsychiatryHome page
L. N. Yatham, P. F. Liddle, R. W. Lam, A. P. Zis, A. J. Stoessl, V. Sossi, M. J. Adam, and T. J. Ruth
Effect of electroconvulsive therapy on brain 5-HT2 receptors in major depression
The British Journal of Psychiatry, June 1, 2010; 196(6): 474 - 479.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
P. Shajahan and M. Taylor
The uses and outcomes of quetiapine in depressive and bipolar mood disorders in clinical practice
J Psychopharmacol, April 1, 2010; 24(4): 565 - 572.
[Abstract] [PDF]

Home page
 Br. J. PsychiatryHome page
R. J. Van Lieshout and G. M. MacQueen
Efficacy and acceptability of mood stabilisers in the treatment of acute bipolar depression: systematic review
The British Journal of Psychiatry, April 1, 2010; 196(4): 266 - 273.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
R. H. Perlis, M. Ostacher, M. Fava, A. A. Nierenberg, G. S. Sachs, and J. F. Rosenbaum
Assuring That Double-Blind Is Blind
Am J Psychiatry, March 1, 2010; 167(3): 250 - 252.
[Full Text] [PDF]

Home page
 J PsychopharmacolHome page
L. W Bisol and D. R Lara
Low-dose quetiapine for patients with dysregulation of hyperthymic and cyclothymic temperaments
J Psychopharmacol, March 1, 2010; 24(3): 421 - 424.
[Abstract] [PDF]

Home page
 Clin TrialsHome page
A. A Nierenberg, L. G Sylvia, A. C Leon, N. A Reilly-Harrington, T. A Ketter, J. R Calabrese, M. E Thase, C. L Bowden, E. S Friedman, M. J Ostacher, et al.
Lithium treatment -- moderate dose use study (LiTMUS) for bipolar disorder: rationale and design
Clinical Trials, December 1, 2009; 6(6): 637 - 648.
[Abstract] [PDF]

Home page
 The Annals of PharmacotherapyHome page
G. T Bogart and B. Chavez
Safety and Efficacy of Quetiapine in Bipolar Depression
Ann. Pharmacother., November 1, 2009; 43(11): 1848 - 1856.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
M. Hassan and M. J. Lage
Risk of rehospitalization among bipolar disorder patients who are nonadherent to antipsychotic therapy after hospital discharge
Am. J. Health Syst. Pharm., February 15, 2009; 66(4): 358 - 365.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. PsychiatryHome page
J. R. Geddes, J. R. Calabrese, and G. M. Goodwin
Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials
The British Journal of Psychiatry, January 1, 2009; 194(1): 4 - 9.
[Abstract] [Full Text] [PDF]

Home page
 PsychosomaticsHome page
A. R. Beckwith
The Precipitation of Mania by Citalopram in a Patient With Interferon-Induced Depression
Psychosomatics, July 1, 2008; 49(4): 362 - 363.
[Full Text] [PDF]

Home page
 J PsychopharmacolHome page
J. Goldberg
On being bipolar without being bipolar
J Psychopharmacol, June 1, 2008; 22(4): 402 - 403.
[PDF]

Home page
 Am. J. PsychiatryHome page
C. D. Schneck, D. J. Miklowitz, S. Miyahara, M. Araga, S. Wisniewski, L. Gyulai, M. H. Allen, M. E. Thase, and G. S. Sachs
The Prospective Course of Rapid-Cycling Bipolar Disorder: Findings From the STEP-BD
Am J Psychiatry, March 1, 2008; 165(3): 370 - 377.
[Abstract] [Full Text] [PDF]

Home page
 J Am Psychiatr Nurses AssocHome page
C. F. Baldassano
Management of Bipolar Disorder in the Acute and Maintenance Settings
Journal of the American Psychiatric Nurses Association, November 1, 2007; 13(5_suppl): S16 - S22.
[Abstract] [PDF]

Home page
 Am. J. PsychiatryHome page
M. A. Frye, H. Grunze, T. Suppes, S. L. McElroy, P. E. Keck Jr., J. Walden, G. S. Leverich, L. L. Altshuler, S. Nakelsky, S. Hwang, et al.
A Placebo-Controlled Evaluation of Adjunctive Modafinil in the Treatment of Bipolar Depression
Am J Psychiatry, August 1, 2007; 164(8): 1242 - 1249.
[Abstract] [Full Text] [PDF]

Home page
 Schizophr BullHome page
C. A. Tamminga and J. M. Davis
The Neuropharmacology of Psychosis
Schizophr Bull, July 1, 2007; 33(4): 937 - 946.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
N. C. Brahm, S. L. Gutierres, and R. M. Carnahan
Quetiapine for acute mania in bipolar disorder
Am. J. Health Syst. Pharm., May 15, 2007; 64(10): 1045 - 1053.
[Abstract] [Full Text] [PDF]

Home page
 APPI Online CMEHome page
References
PsychiatryOnline CME, May 1, 2007; 2007(1): 2 - 2.
[Full Text]

Home page
 Arch Gen PsychiatryHome page
H. Scherk, F. G. Pajonk, and S. Leucht
Second-Generation Antipsychotic Agents in the Treatment of Acute Mania: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Arch Gen Psychiatry, April 1, 2007; 64(4): 442 - 455.
[Abstract] [Full Text] [PDF]

Home page
 FocusHome page
G. S. Sachs
Bipolar Disorder Clinical Synthesis: Where Does the Evidence Lead?
Focus, January 1, 2007; 5(1): 3 - 13.
[Abstract] [Full Text] [PDF]

Home page
 FocusHome page
S. N. Ghaemi
Ask the Expert: TREATMENT OF PATIENT WITH BIPOLAR DISORDER AND DEPRESSION
Focus, January 1, 2007; 5(1): 18 - 19.
[Full Text] [PDF]

Home page
 FocusHome page
R. M. A. Hirschfeld
Guideline Watch (November 2005): Practice Guideline for the Treatment of Patients with Bipolar Disorder, 2nd Edition
Focus, January 1, 2007; 5(1): 34 - 39.
[Abstract] [Full Text] [PDF]

Home page
 FocusHome page
Bibliography BIPOLAR DISORDER
Focus, January 1, 2007; 5(1): 40 - 43.
[Full Text] [PDF]

Home page
 FocusHome page
M. Gitlin
Treatment-Resistant Bipolar Disorder
Focus, January 1, 2007; 5(1): 49 - 63.
[Abstract] [Full Text] [PDF]

Home page
 FocusHome page
G. S. Leverich, L. L. Altshuler, M. A. Frye, T. Suppes, S. L. McElroy, P. E. Keck Jr., R. W. Kupka, K. D. Denicoff, W. A. Nolen, H. Grunze, et al.
Risk of Switch in Mood Polarity to Hypomania or Mania in Patients With Bipolar Depression During Acute and Continuation Trials of Venlafaxine, Sertraline, and Bupropion as Adjuncts to Mood Stabilizers
Focus, January 1, 2007; 5(1): 98 - 106.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
R. S. El-Mallakh and A. Karippot
Chronic Depression in Bipolar Disorder
Am J Psychiatry, August 1, 2006; 163(8): 1337 - 1341.
[Full Text] [PDF]

Home page
 Arch Gen PsychiatryHome page
M. Olfson, C. Blanco, L. Liu, C. Moreno, and G. Laje
National trends in the outpatient treatment of children and adolescents with antipsychotic drugs.
Arch Gen Psychiatry, June 1, 2006; 63(6): 679 - 685.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
A. A. Nierenberg, M. J. Ostacher, J. R. Calabrese, T. A. Ketter, L. B. Marangell, D. J. Miklowitz, S. Miyahara, M. S. Bauer, M. E. Thase, S. R. Wisniewski, et al.
Treatment-Resistant Bipolar Depression: A STEP-BD Equipoise Randomized Effectiveness Trial of Antidepressant Augmentation With Lamotrigine, Inositol, or Risperidone
Am J Psychiatry, February 1, 2006; 163(2): 210 - 216.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
G. S. Leverich, L. L. Altshuler, M. A. Frye, T. Suppes, S. L. McElroy, P. E. Keck Jr., R. W. Kupka, K. D. Denicoff, W. A. Nolen, H. Grunze, et al.
Risk of Switch in Mood Polarity to Hypomania or Mania in Patients With Bipolar Depression During Acute and Continuation Trials of Venlafaxine, Sertraline, and Bupropion as Adjuncts to Mood Stabilizers
Am J Psychiatry, February 1, 2006; 163(2): 232 - 239.
[Abstract] [Full Text] [PDF]

Home page
 Evid. Based Ment. HealthHome page
Other articles noted
Evid. Based Ment. Health, February 1, 2006; 9(1): 4 - 4.
[Full Text] [PDF]


Get information about faster international access.

Privacy Policy

Copyright © 2005 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org